An Interaction Study of LY3200882 in Healthy Participants
Completed
Eli Lilly and Company
Phase 1
The main purpose of this study is to evaluate the effect of itraconazole on the amount of
LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety
and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is
expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will
occur up to 28 days prior to enrollment.
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Unknown status
Agendia
Phase 1/Phase 2
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the
combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU
or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the
LY3200882 plus capecitabine combination in patients with chemo-resistant CRC. The combination
of LY3200882 plus capecitabine will be given as second line therapy in the phase II part of
this study.
Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received
a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined
with oxaliplatin and, depending upon local hospital preferences or national guidelines, also
bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of LY3200882
to capecitabine should thus result in reversal of unresponsiveness, which is the first step
in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced
CRC and is thus attractive for this study concept. If proof of principle is achieved also
other tumor types can be explored with this genetic makeup, such as non-small cell lung
cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line,
usually cisplatin/carboplatin-pemetrexed in non-squamous and
cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
